Chengdu Kanghong Pharmaceutical Group Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000020C4
CNY
30.97
0.45 (1.47%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Mar 25

  • OPERATING CASH FLOW(Y) Highest at CNY 1,486.73 MM
  • DEBT-EQUITY RATIO (HY) Lowest at -67.07 %
  • DEBTORS TURNOVER RATIO(HY) Highest at 22.58%
2

With ROE of 13.70%, it has a attractive valuation with a 2.85 Price to Book Value

3

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 25,302 Million (Large Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.18%

stock-summary
Debt Equity

-0.68

stock-summary
Return on Equity

13.70%

stock-summary
Price to Book

2.85

Revenue and Profits:
Net Sales:
1,237 Million
(Quarterly Results - Jun 2025)
Net Profit:
325 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.85%
0%
-24.85%
6 Months
-0.77%
0%
-0.77%
1 Year
52.04%
0%
52.04%
2 Years
64.82%
0%
64.82%
3 Years
90.7%
0%
90.7%
4 Years
67.86%
0%
67.86%
5 Years
-30.31%
0%
-30.31%

Chengdu Kanghong Pharmaceutical Group Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.05%
EBIT Growth (5y)
13.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.50
Tax Ratio
12.21%
Dividend Payout Ratio
46.33%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.39%
ROE (avg)
9.96%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.85
EV to EBIT
15.02
EV to EBITDA
12.69
EV to Capital Employed
6.74
EV to Sales
4.24
PEG Ratio
17.27
Dividend Yield
2.18%
ROCE (Latest)
44.83%
ROE (Latest)
13.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.36% vs 15.65% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -18.00% vs 86.99% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,237.10",
          "val2": "1,185.40",
          "chgp": "4.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "427.80",
          "val2": "493.90",
          "chgp": "-13.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-1.00",
          "chgp": "10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "325.20",
          "val2": "396.60",
          "chgp": "-18.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "297.90%",
          "val2": "366.60%",
          "chgp": "-6.87%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.62% vs 16.79% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.15% vs 19.09% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,393.70",
          "val2": "3,901.40",
          "chgp": "12.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,465.20",
          "val2": "1,324.60",
          "chgp": "10.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "-0.80",
          "chgp": "137.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,177.00",
          "val2": "1,031.10",
          "chgp": "14.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "280.30%",
          "val2": "281.70%",
          "chgp": "-0.14%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,237.10
1,185.40
4.36%
Operating Profit (PBDIT) excl Other Income
427.80
493.90
-13.38%
Interest
0.00
0.00
Exceptional Items
-0.90
-1.00
10.00%
Consolidate Net Profit
325.20
396.60
-18.00%
Operating Profit Margin (Excl OI)
297.90%
366.60%
-6.87%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.36% vs 15.65% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -18.00% vs 86.99% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4,393.70
3,901.40
12.62%
Operating Profit (PBDIT) excl Other Income
1,465.20
1,324.60
10.61%
Interest
0.40
0.30
33.33%
Exceptional Items
0.30
-0.80
137.50%
Consolidate Net Profit
1,177.00
1,031.10
14.15%
Operating Profit Margin (Excl OI)
280.30%
281.70%
-0.14%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 12.62% vs 16.79% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.15% vs 19.09% in Dec 2023

stock-summaryCompany CV
About Chengdu Kanghong Pharmaceutical Group Co., Ltd. stock-summary
stock-summary
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available